Short Interest in Autonomix Medical, Inc. (NASDAQ:AMIX) Drops By 58.7%

Autonomix Medical, Inc. (NASDAQ:AMIX) was the target of a large decline in short interest in August. As of August 14th, there was short interest totaling 108,801 shares, a decline of 58.7% from the July 30th total of 263,441 shares. Based on an average daily volume of 13,826,443 shares, the short-interest ratio is currently 0.0 days. Currently, 11.9% of the company’s stock are sold short.

Analyst Ratings Changes

AMIX has been the subject of several research analyst reports. Weiss Ratings upgraded Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. Zacks Research upgraded shares of Autonomix Medical to a “hold” rating in a report on Tuesday, June 2nd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $42.00.

Autonomix Medical Trading Down 11.8%

AMIX opened at $5.63 on Friday. The stock has a market capitalization of $5.46 million, a P/E ratio of -0.14 and a beta of -1.17. Autonomix Medical has a 12 month low of $2.44 and a 12 month high of $32.55. The firm’s fifty day simple moving average is $6.39 and its 200 day simple moving average is $7.57.

Autonomix Medical (NASDAQ:AMIX) last released its earnings results on Wednesday, August 12th. The company reported ($5.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.40) by $1.38. On average, equities research analysts predict that Autonomix Medical will post -20.17 EPS for the current fiscal year.

Autonomix Medical Company Profile

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.